Some good views here. It appears to be changing from an undervalued asset situation to an earnings story. It is interesting that Temozolomide in their numbers which should add $15m to EBITDA in time. (refer Morgans report).
Looking for good news flow over the next 18 months.
New Analyst Rating price target $0.37 ..., page-10
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IDT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.8¢ |
Change
0.003(2.17%) |
Mkt cap ! $50.50M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 12.0¢ | 11.8¢ | $3.122K | 26.01K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 360500 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 130253 | 5 |
View Market Depth
| Last trade - 15.42pm 18/09/2024 (20 minute delay) ? |
| IDT (ASX) Chart |